Results 51 to 60 of about 7,531 (200)
Human Vaccines & Immunotherapeutics, 2018 In spite of current influenza vaccines being immunogenic, evolution of the influenza virus can reduce efficacy and so influenza remains a major threat to public health.
John S. Tregoning +2 more
doaj +1 more source
Frontiers in Immunology, 2019 Immaturity of the immune system contributes to poor vaccine responses in early life. Germinal center (GC) activation is limited due to poorly developed follicular dendritic cells (FDC), causing generation of few antibody-secreting cells (ASCs) with ...
Audur Anna Aradottir Pind +15 more
doaj +1 more source
A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis [PDF]
Iranian Journal of Basic Medical Sciences, 2016 Objective(s): In this study, for the first time, MF59 adjuvant was used to develop a cholesteryl ester transfer protein (CETP) vaccine. The efficacy of the vaccine was compared with the efficacy of CETP vaccine formulated with Alum/CpG, the formulation ...
Tamara Aghebati +9 more
doaj +1 more source
Advanced Science, EarlyView.This study developed a novel nano‐vaccine (Ferritin‐PC@PBNZs) comprising a ferritin‐based scaffold for the multivalent display of phosphorylcholine (PC) antigens, integrated with Prussian blue nanozymes (PBNZs) as a potent adjuvant. By leveraging the ferritin carrier for high‐density and ordered antigen display, the nano‐vaccine significantly augments ...
Jingyi Sheng +6 more
wiley +1 more source
PLoS ONE, 2012 Adjuvant formulations capable of inducing high titer and high affinity antibody responses would provide a major advance in the development of vaccines to viral infections such as HIV-1. Although oil-in-water emulsions, such as Freund's adjuvant (FCA/FIA),
Rachel P J Lai +12 more
doaj +1 more source
Estimation of the health impact and cost-effectiveness of influenza vaccination with enhanced effectiveness in Canada. [PDF]
PLoS ONE, 2011 INTRODUCTION: The propensity for influenza viruses to mutate and recombine makes them both a familiar threat and a prototype emerging infectious disease.
David N Fisman, Ashleigh R Tuite
doaj +1 more source
Large Language Models for Clinical Trial Protocol Assessments
Clinical Pharmacology &Therapeutics, Volume 119, Issue 2, Page 393-402, February 2026.The purpose was to evaluate the utility of large language models (LLMs) for reviewing the statistical analysis plan (SAP) and pharmacokinetics–pharmacodynamics (PK–PD) components of clinical trial protocols. Clinical trial protocols and SAPs were obtained from clinicaltrials.gov for a testbed of 15 small‐molecule drugs, biologics, and global antibiotic
Euibeom Shin +2 more
wiley +1 more source
Human Vaccines & Immunotherapeutics, 2019 Seasonal influenza is a very common disease. Yearly vaccination of at-risk population groups is a well-recognized cost-effective/cost-saving preventive measure.
Ilaria Loperto +3 more
doaj +1 more source
Hydroxypropyl Cellulose Enhances Immune Responses to the Current Seasonal Influenza Vaccine in Mice
Microbiology and Immunology, Volume 70, Issue 2, Page 68-79, February 2026.ABSTRACT Influenza A and B viruses cause annual epidemics and continue to pose global public health concerns. The most effective approach to preventing or mitigating the severity of influenza is vaccination. Inactivated split influenza HA vaccines are commonly used worldwide due to their strong safety profile and broad range of target groups; however ...
Nantaporn Kaewaroon +4 more
wiley +1 more source
Advanced Science, Volume 13, Issue 6, 30 January 2026.Challenging the focus on age, this study finds pre‐existing T helper 1 cells are the key biomarker for predicting antibody response to SARS‐CoV‐2 inactivated vaccines. In both mice and humans, high responders exhibited elevated baseline T helper 1 cells, which correlated with robust humoral immunity, offering crucial guidance for improving vaccine ...
Chanyuan Ye +12 more
wiley +1 more source